4-Phenyl-piperazine-1-carboxylic acid (2-pyridin-2-yl-ethyl)-amide | 127571-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-Phenyl-piperazine-1-carboxylic acid (2-pyridin-2-yl-ethyl)-amide
• 英文别名: 4-phenyl-N-(2-pyridin-2-ylethyl)piperazine-1-carboxamide
• CAS: 127571-22-6
• 化学式: C₁₈H₂₂N₄O
• 分子量: 310.399
• InChiKey: CAZXJYFZQWBHIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-苯基哌嗪 、 2-(2-氯乙基)吡啶 生成 4-Phenyl-piperazine-1-carboxylic acid (2-pyridin-2-yl-ethyl)-amide
  参考文献：
  名称：

  WALSH, DAVID A.;GREEN, JERRY B.;FRANZYSHEN, STEPHEN K.;NOLAN, JOSEPH C.;Y+, J. MED. CHEM., 33,(1990) N, C. 2028-2032

  摘要：

  DOI：

文献信息

• [EN] NEW COMPOUNDS V<br/>[FR] NOUVEAUX COMPOSÉS V
  申请人：BIOVITRUM AB PUBL

  公开号：WO2009147211A1

  公开（公告）日：2009-12-10

  The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

  本发明涉及式(I)的新化合物，包含这些化合物的药物组合物，以及这些化合物作为瘦素受体调节剂模拟物在制备用于治疗与体重增加、2型糖尿病和血脂异常相关的药物的用途。
• PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS
  申请人：Chapman Emma

  公开号：US20110275637A1

  公开（公告）日：2011-11-10

  The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

  本发明涉及式（I）的新化合物，包括这些化合物的制药组合物，以及这些化合物作为瘦素受体调节剂类似物在制备用于治疗与体重增加、2型糖尿病和脂质代谢异常相关的疾病的药物中的应用。
• Synthesis and antiallergy activity of N-[2-(dimethylamino)ethyl]-4-aryl-1-piperazinecarboxamide derivatives
  作者：David A. Walsh、Jerry B. Green、Stephen K. Franzyshen、Joseph C. Nolan、John M. Yanni

  DOI：10.1021/jm00169a037

  日期：1990.7

  A series of N-[2-(dimethylamino)ethyl]-4-aryl-1-piperazinecarboxamides was synthesized and evaluated for antiallergy activity. Several derivatives had activity in the passive foot anaphylaxis (PFA) assay, an IgE-mediated model useful in the detection of compounds possessing antiallergic activity, but no derivative tested had activity at 10 mg/kg in the guinea pig anaphylaxis (GPA) assay. One analogue, N-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-1-piperazinecarboxamide , had an IC50 = 310 nM for inhibition of tritiated mepyramine binding to H1 histaminic receptors isolated from guinea pig cerebral cortex.
• NEW COMPOUNDS V
  申请人：AstraZeneca AB (Publ)

  公开号：EP2313096A1

  公开（公告）日：2011-04-27